| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Adalgiase (0.001-10 μg/mL; 72 hours) effectively inhibited the activity of ASS1-negative MIA PaCa-2 and PANC-1 pancreatic cancer cells, but had no inhibitory effect on ASS1-positive SMMC7721 hepatocellular carcinoma cells [1]. Adalgiase (0.1 μg/mL; 6-96 hours) induced activation of the autophagy pathway (increased levels of LC3-II, Beclin 1, and phosphorylated AMPKα) and the apoptosis pathway (decreased levels of PARP-1) in MIA PaCa-2 pancreatic cancer cells [1]. Adalgiase (0.001-1 μg/mL; 72 hours) had no effect on NEI-01-adapted MIA PaCa-2 pancreatic cancer cells, but after culturing in NEI-01-free medium for 96 hours, these cells were resensitized to NEI-01 [1].
|
|---|---|
| ln Vivo |
NEI-01 (adageminase) (2-5 U; intraperitoneal injection; twice weekly) significantly reduced the volume and weight of pancreatic tumors in a mouse xenograft model [1].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: Human pancreatic cancer cell lines (MIA PaCa-2, PANC-1), human liver cancer cell line (SMMC7721) Tested Concentrations: 0.001-10 μg/mL Incubation Duration: 72 hours Experimental Results: It inhibited the viability of ASS1-negative MIA PaCa-2 cells, with an IC50 of 0.086 μg/mL. It inhibited the viability of ASS1-negative PANC-1 cells, with an IC50 of 0.190 μg/mL. It did not show a significant inhibitory effect on ASS1-positive SMMC7721 cells, with an IC50 >10 μg/mL. Western Blot Analysis [1] Cell Types: MIA PaCa-2 human pancreatic cancer cell line Tested Concentrations: 0.1 μg/mL Incubation Duration: 6-96 hours Experimental Results: LC3-II, Beclin 1, and phosphorylated AMPKα levels were increased. PARP-1 levels were decreased. This indicates that both autophagy and apoptosis pathways were activated. Cell viability assay [1] Cell Types: NEI-01 adapted and eluted MIA PaCa-2 human pancreatic cancer cell lines Tested Concentrations: 0.001-1 μg/mL Incubation Duration: 72 hours Experimental Results: NEI-01 adapted MIA PaCa-2 cells showed resistance to NEI-01 treatment. Eluted MIA PaCa-2 cells were resensitive to NEI-01 with an IC50 of 0.012 μg/mL. |
| Animal Protocol |
Animal/Disease Models:BALB/c female athymic nude mice (4-6 weeks old; pancreatic cancer xenograft model) [1]
Doses: 2 U; 5 U Route of Administration: Intraperitoneal injection; twice weekly Experimental Results: Tumor volume was significantly reduced compared to the control group (2 U dose). Tumor volume (p < 0.01) and tumor weight (p = 0.004) were significantly reduced compared to the control group (5 U dose). Plasma arginine levels decreased during the experiment. Only a slight increase in ASS1 expression was induced in tumor tissue. |
| References |
| Appearance |
Typically exists as solids at room temperature
|
|---|---|
| Synonyms |
NEI-01
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
